Positive Results From Phase III Trial Of Gamunex(R) In Patients With CIDP

In the largest trial ever reported in CIDP (chronic inflammatory demyelinating polyradiculoneuropathy), Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) was shown to reduce functional disability, while also demonstrating a prolonged time to relapse and a decreased probability of relapse longer-term (up to one year).

More: continued here

Filed under: Clinical Trials on February 11th, 2008